Article Text

other Versions

PDF
Management of Lipid Exudates in Coats’ Disease by Intravitreal Triamcinolone: Effects and Complications
  1. Ihab Saad Othman1,*,
  2. Magdy Moussa2,
  3. Manal Bouhaimed3
  1. 1 Department of Ophthalmology, Facult of Medicine, Cairo University, Cairo, Egypt;
  2. 2 Department of Ophthalmology, Tanta University, Tanta, Egypt;
  3. 3 Faculty of Medicine, Kuwait University. The State of Kuwait, Kuwait
  1. Correspondence to: Ihab Saad Othman, Ophthalmology, Associate Professor, Cairo University, Egypt, 6 Tahrir Street, Dokki, Giza, 11111, Egypt; ihabsaad{at}hotmail.com

Abstract

Aim: To evaluate the role of intravitreal Triamcinolone (TA) in the early management of Coats’ disease.

Methods: Prospective, interventional case series.

Results: Fifteen consecutive cases with Coats’ disease were managed with 4mg/0.1ml intravitreal Triamcinolone injection on presentation and were followed for a minimum of one year duration. Additional management strategies including drainage of subretinal fluid through an inferior sclerotomy, peripheral laser ablation and/or cryotherapy, cataract extraction, and vitrectomy were performed. Improvement of visual acuity could be achieved compared to preoperative vision in all cases in this series even when 40% needed cataract extraction with intra ocular lens implantation. One patient needed anti glaucoma treatment to control raised intraocular pressure in this series.

Conclusion: Triamcinolone has a role in improving the rate of absorption of subretinal fluid and macular exudates in Coats’ disease. Major complication of 4mg/0.1 ml intravitreal triamcinolone is cataract in 40 % of cases in children.

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.